X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Blood

• Publication date

  2005-11-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD-2005-09-3900PMID 16434490PMCID PMC1895292
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical implications of the JAK2 V617F mutation in essential thrombocythemia

  2005cited by this paper
• Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

  2005cited by this paper
• Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

  2005influential reference
• Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

  2005cited by this paper
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

  2005cited by this paper
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

  2005cited by this paper
• The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients.

  2005cited by this paper
• A gain-of-function mutation of JAK2 in myeloproliferative disorders.

  2005cited by this paper
• Identification of an Acquired JAK2 Mutation in Polycythemia Vera*

  2005cited by this paper
• BFU-E response to erythropoietin accurate clonality assays and comparison with PRV-1 expression and Discrimination of polycythemias and thrombocytoses by novel , simple

  2003cited by this paper
• Clonality analysis using X-chromosome inactivation at the human androgen receptor gene (Humara). Evaluation of large cohorts of patients with chronic myeloproliferative diseases, secondary neutrophilia, and reactive thrombocytosis.

  1999cited by this paper
• X-inactivation analysis in the 1990s: promise and potential problems

  1998cited by this paper
• Acquired skewing of X‐chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age

  1997cited by this paper
• Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age.

  1996cited by this paper
• Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease.

  1994cited by this paper
• Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction.

  1991cited by this paper
• Polycythemia vera: stem-cell and probable clonal origin of the disease.

  1976cited by this paper
• The analysis of binary data

  1971cited by this paper
• Some speculations on the myeloproliferative syndromes.

  1951cited by this paper
• Editorial: Some Speculations on the Myeloproliferative Syndromes

  1951cited by this paper
• Probability tables for individual comparisons by ranking methods.

  1947cited by this paper
• Individual Comparisons by Ranking Methods

  1945cited by this paper

• Frequency of JAK2V617F Mutation Zygosity and Impact on Disease Outcome in MPN Patients

  2025cites this paper
• Incidence and risk factors for second malignancies among patients with myeloproliferative neoplasms

  2023cites this paper
• Allelic burden of Janus kinase 2 in a 6-month course of therapy for myeloproliferative neoplasms

  2023cites this paper
• Clonal hematopoiesis with JAK2V617F promotes pulmonary hypertension with ALK1 upregulation in lung neutrophils

  2021cites this paper
• An Asian-specific MPL genetic variant alters JAK-STAT signaling and influences platelet count in the population.

  2021cites this paper
• The JAK2 mutation.

  2021cites this paper
• A circulating subset of BRAFV600E‐positive cells in infants with high‐risk Langerhans cell histiocytosis treated with BRAF inhibitors

  2021cites this paper
• Single cell mutational profiling delineates clonal trajectories in myeloid malignancies

  2020cites this paper
• Myeloproliferative neoplasms

  2020cites this paper
• Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses

  2020cites this paper
• Single cell mutation analysis of clonal evolution in myeloid malignancies

  2020cites this paper
• Inhibition of JAK2 Suppresses Myelopoiesis and Atherosclerosis in Apoe−/− Mice

  2020cites this paper
• Chapter 2 Genetics of the Myeloproliferative Neoplasms

  2019cites this paper
• Thrombocytosis

  2019cites this paper
• Recurrent cerebral venous sinus thrombosis in a young man- A case report of JAK2-negative polycythemia vera

  2019cites this paper
• Jak2v617f Mutation in Patients With Myeloproliferative Diseases And Those With Ischemic Heart Disease With Normal Coronary Angiography

  2019cites this paper
• Clinicopathological spectrum of BCR-ABL-Negative myeloproliferative neoplasms with correlation with janus-associated kinase 2 mutation

  2019cites this paper
• JAK2ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera.

  2019cites this paper
• Clonal Hematopoiesis: Somatic Mutations in Blood Cells and Atherosclerosis

  2018cites this paper
• A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs

  2018cites this paper
• The JAK2 GGCC (46/1) Haplotype in Myeloproliferative Neoplasms: Causal or Random?

  2018cites this paper
• Retrospective analysis of patients with chronic myeloproliferative neoplasms: a single center experience

  2018cites this paper
• Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis

  2018cites this paper
• Roles of germline JAK2 activation mutation JAK2 V625F in the pathology of myeloproliferative neoplasms.

  2018cites this paper
• Molecular Biology of Leukemias

  2017cites this paper
• How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes

  2017cites this paper
• Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs)

  2017cites this paper
• Maladie de Vaquez

  2017cites this paper
• Mutations in myeloproliferative neoplasms – their significance and clinical use

  2017cites this paper
• Brief report Characteristics and clinical correlates of MPL 515WL/K mutation in essential thrombocythemia

  2016cites this paper
• Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

  2016cites this paper
• Insights into the Structural Features Essential for JAK2 Inhibition and Selectivity.

  2016cites this paper
• Prognosis of Primary Myelofibrosis in the Genomic Era.

  2016cites this paper
• Molecular characterisation of triple negative essential thrombocythaemia patients by platelet analysis and targeted sequencing

  2016cites this paper
• Association Between Soluble CD40L with Thrombosis Occurrence and JAK2 V617F Mutation in Essential Thrombocythemia

  2016cites this paper
• Mass Cytometry Analysis Reveals Hyperactive NF Kappa B Signaling in Myelofibrosis and Secondary Acute Myeloid Leukemia

  2016cites this paper
• Expressão gênica de metaloproteinases e de seus reguladores em neoplasias mieloproliferativas: associação com biomarcadores de angiogênese e status mutacional

  2016cites this paper
• Detection of mutations in JAK2 exons 12–15 by Sanger sequencing

  2016cites this paper
• SOHO Supplement 2016 Prognosis of Primary Myelo fi brosis in the Genomic Era

  2016cites this paper
• Incidence and risk factors for myelofibrotic transformation among 272 Chinese patients with JAK2‐mutated polycythemia vera

  2015cites this paper
• Hemophagocytic lymphohistiocytosis in a female patient due to a heterozygous XIAP mutation and skewed X chromosome inactivation

  2015cites this paper
• Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders.

  2015cites this paper
• Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands.

  2015cites this paper
• Mechanisms of thrombogenesis in polycythemia vera.

  2015cites this paper
• JAK2V617F mediates resistance to DNA damage-induced apoptosis by modulating FOXO3A localization and Bcl-xL deamidation

  2015cites this paper
• Incidence of JAK2V617F Mutation in Patients with Acute Myeloid Leukemia

  2015cites this paper
• Incidence and risk factors for myelofibrotic transformation among 272 Chinese patients with JAK2-mutated polycythemia vera.

  2015cites this paper
• Demonstration of the Cell Clonality in Canine Hematopoietic Tumors by X-chromosome Inactivation Pattern Analysis

  2015cites this paper
• ... .165-DETECTION OF JAK2 MUTATION BY PCR TECHNIQUE IN CHRONIC MYELOPROLIFERATIVE DISORDERS

  2014cites this paper
• X chromosome inactivation analysis reveals a difference in the biology of ET patients with JAK2 and CALR mutations.

  2014cites this paper
• Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea

  2014cites this paper
• The role of serum erythropoietin level and jak2 v617f allele burden in the diagnosis of polycythaemia vera

  2014cites this paper
• The Frequency Of JAK2 V617F Gen Mutation And Its Associations With Whole Blood Count Parameters

  2014cites this paper
• pathway activation in myeloproliferative neoplasm pathogenesis Integrated genomic analysis illustrates the central role of JAK-STAT

  2014cites this paper
• JAK 2 V617F gen mutasyon sikliği ve tam kan sayimi parametreleri ile ilişkisi

  2014cites this paper
• JAK2 mutation and treatment of JAK2 inhibitors in Philadelphia chromosome-negative myeloproliferative neoplasms

  2014cites this paper
• JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: Clinical usefulness for predicting myelofibrotic transformation and thrombotic events

  2014cites this paper
• Detection of JAK2 V617F mutation increases the diagnosis of myeloproliferative neoplasms

  2014cites this paper
• Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.

  2014cites this paper
• A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis.

  2014cites this paper
• Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors.

  2014cites this paper
• years show that minor mutant-positive clones can remain stable for many JAK2 V617F mutant levels in patients with essential thrombocythemia Long-term serial analysis of X-chromosome inactivation patterns and

  2013cites this paper
• Validation of Standards for Quantitative Assessment of JAK2 c.1849G>T (p.V617F) Allele Burden Analysis in Clinical Samples

  2013cites this paper
• CD133 marks a stem cell population that drives human primary myelofibrosis

  2013cites this paper
• between quantitative JAK2 V617F and Mpl expression Molecular mimicry in the chronic myeloproliferative disorders: reciprocity

  2013cites this paper
• CAPÍTULO 3 – Biología molecular de la trombocitemia esencial negativa a JAK2

  2013cites this paper
• reliability and utility for identifying disease subtypes Bone marrow pathology in essential thrombocythemia: interobserver

  2013cites this paper
• essential thrombocythemia Characteristics and clinical correlates of MPL 515W>L/K mutation in

  2013cites this paper
• Kronik Miyeloproliferatif Hastaliklarda JAK2V617F Mutasyonu JAK2V617F Mutation in Chronic Myeloproliferative Disorders

  2013cites this paper
• A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

  2013cites this paper
• Three-year ef fi cacy, safety, and survival fi ndings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelo fi brosis

  2013cites this paper
• Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage

  2013cites this paper
• Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study

  2013cites this paper
• Proteomic analysis reveals heat shock protein 70 has a key role in polycythemia Vera

  2013cites this paper
• Genetic predisposition to molecular response in patients with myeloproliferative neoplasms treated with hydroxycarbamide.

  2013cites this paper
• 2-Amino-[1,2,4]triazolo[1,5-a]pyridines as JAK2 inhibitors.

  2013cites this paper
• Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.

  2013cites this paper
• Posterior Pole Manifestations of Hematologic Diseases

  2013cites this paper
• myelofibrosis phase 3 study comparing ruxolitinib with best available therapy for Three-year efficacy, safety, and survival findings from COMFORT-II, a

  2013cites this paper
• JAK2V617F-positive Myeloproliferative Neoplasms : KI mouse models, Interferon-α therapy and clonal architecture

  2013cites this paper
• Polycythemia vera and essential thrombocythemia: new developments in biology with therapeutic implications.

  2013cites this paper
• Clonal Evolution Revealed by Whole Genome Sequencing in a Case of Primary Myelofibrosis Transformed to Secondary Acute Myeloid Leukemia

  2012cites this paper
• Utilidad de la cuantificación de la carga mutacional de JAK2V617F en neoplasias mieloproliferativas crónicas Ph negativas clásicas

  2012cites this paper
• JAK2-V617F Mutation and BCR-ABL Rearrangement in Chronic Myeloproliferative Neoplasms

  2012influential citation
• The Role of Janus Kinases in Hematopoietic Malignancies

  2012cites this paper
• X-Chromosome Inactivation Pattern Analysis for the Assessment of Cell Clonality in Cats

  2012cites this paper
• JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone.

  2012cites this paper
• The cell cycle regulator CDC25A is a target for JAK2V617F oncogene.

  2012cites this paper
• Clinical significance of clonality assessment in JAK2V617F-negative essential thrombocythemia

  2012cites this paper
• The cell cycle regulator CDC 25 A is a target for JAK 2 V 617 F oncogene

  2012cites this paper
• JAK2 V617F, MPL W515L and JAK2 exon 12 mutations in Chinese patients with primary myelofibrosis

  2012cites this paper
• Myeloid malignancies: mutations, models and management

  2012cites this paper
• The role of HMGA2 in the proliferation and expansion of a hematopoietic cell in myeloproliferative neoplasms.

  2012cites this paper
• TET2 is essential for survival and hematopoietic stem cell homeostasis

  2012cites this paper
• Myeloproliferative neoplasm animal models.

  2012cites this paper
• Identification of a HMGA2-EFCAB6 gene rearrangement following next-generation sequencing in a patient with a t(12;22)(q14.3;q13.2) and JAK2V617F-positive myeloproliferative neoplasm.

  2012cites this paper
• Thrombopoietin and hematopoietic stem cells

  2011cites this paper
• Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients

  2011cites this paper
• New mutations and pathogenesis of myeloproliferative neoplasms.

  2011cites this paper
• Investigations into the molecular pathogenesis of essential thrombocythaemia

  2011cites this paper